<i><scp>HCV E1E</scp>2‐<scp>MF</scp>59</i> vaccine in chronic hepatitis <scp>C</scp> patients treated with <scp>PEG</scp>‐<scp>IFN</scp>α2a and <scp>R</scp>ibavirin: a randomized controlled trialP. Colombatto, Ferruccio Bonino, Michael Houghton et al.|Journal of Viral Hepatitis|2013Cited by 22
Prevalence of anti-HCV among spouses and offspring of anti-HCV positive subjects: an Italian multicentre study.N. Caporaso, Gianni Pastore, Antonio Ascione et al.|PubMed|1995Cited by 19
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational studySalvatore Petta, S. Fagiuoli, Marco Marzioni et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 19
Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experienceAntonio Ascione, Vincenzo Messina, Cleo Study Group et al.|World Journal of Hepatology|2016Cited by 9
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosisAntonio Ascione, N. Caporaso, M. De Luca et al.|Infection|2018Cited by 8